Adjuvant Capital invests in life sciences technologies addressing critical global public health challenges, particularly in emerging economies. By focusing on underserved markets and leveraging expertise to accelerate impactful innovations, the firm aims to generate both financial and social returns. The firm targets innovations in infectious diseases (HIV/AIDS, tuberculosis, malaria, tropical diseases, pandemics), maternal/child health, nutrition, and reproductive/sexual health, with a preference for technologies that have already proven safety and efficacy in humans.
Bevorzugte Reifephase für die erste Finanzierung.
High-burden public health challenges, neglected infectious diseases, maternal and child health, nutrition, reproductive and sexual health, antimicrobial resistance, pandemic threats
Thematische Schwerpunkte und Zielmarktsegmente von Interesse.
Standard-Finanzierungsbetrag pro Runde.
Verifiziertes E-Mail-Muster
Analysen-Scorecard der Investitionsthese
Unser KI-Analyzer hat Portfolio-Unternehmen gescannt und verifizierte Übereinstimmungen berechnet...
